Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

NCT04300647 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04300647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04300647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2020
Completion date
February 24, 2025
Enrollment
172 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer